




RealRate

PHARMACEUTICAL 2018

Ayala Pharmaceuticals Inc
Rank 238 of 332

ADVAXIS
IMMUNOTHERAPIES™



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Ayala Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 177%, being 75% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	81,243
Cost of Goods Sold	0
Intangible Assets	4,857
Liabilities, Current	20,864
Liabilities, Non-Current	1,039
Other Assets	431
Other Compr. Net Income	0
Other Expenses	-4,403
Other Liabilities	17,479
Other Net Income	690
Other Revenues	12,031
Property and Equipment	7,111
Research and Development	71,900
Selling, General and Administrative Expense	38,658

Output Variable	Value in 1000 USD
Assets	93,642
Liabilities	39,382
Expenses	106,156
Revenues	12,031
Stockholders Equity	54,260
Net Income	-93,435
Comprehensive Net Income	-93,435
BaseVar	125,950
ECR before LimitedLiability	37%
Economic Capital Ratio	177%